These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

362 related items for PubMed ID: 26546477

  • 1. Edoxaban: A Review in Deep Vein Thrombosis and Pulmonary Embolism.
    Shirley M, Dhillon S.
    Drugs; 2015 Nov; 75(17):2025-34. PubMed ID: 26546477
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial.
    Nakamura M, Wang YQ, Wang C, Oh D, Yin WH, Kimura T, Miyazaki K, Abe K, Mercuri M, Lee LH, Segers A, Büller H.
    J Thromb Haemost; 2015 Sep; 13(9):1606-14. PubMed ID: 26179767
    [Abstract] [Full Text] [Related]

  • 3. Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study.
    van Es N, Di Nisio M, Bleker SM, Segers A, Mercuri MF, Schwocho L, Kakkar A, Weitz JI, Beyer-Westendorf J, Boda Z, Carrier M, Chlumsky J, Décousus H, Garcia D, Gibbs H, Kamphuisen PW, Monreal M, Ockelford P, Pabinger I, Verhamme P, Grosso MA, Büller HR, Raskob GE.
    Thromb Haemost; 2015 Nov 25; 114(6):1268-76. PubMed ID: 26271200
    [Abstract] [Full Text] [Related]

  • 4. [Hokusai-VTE: edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism].
    Sprynger M.
    Rev Med Liege; 2013 Oct 25; 68(10):548-51. PubMed ID: 24298731
    [Abstract] [Full Text] [Related]

  • 5. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study.
    Brekelmans MP, Ageno W, Beenen LF, Brenner B, Buller HR, Chen CZ, Cohen AT, Grosso MA, Meyer G, Raskob G, Segers A, Vanassche T, Verhamme P, Wells PS, Zhang G, Weitz JI.
    Lancet Haematol; 2016 Sep 25; 3(9):e437-45. PubMed ID: 27570090
    [Abstract] [Full Text] [Related]

  • 6. Edoxaban Exposure-Response Analysis and Clinical Utility Index Assessment in Patients With Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism.
    Nyberg J, Karlsson KE, Jönsson S, Yin O, Miller R, Karlsson MO, Simonsson U.
    CPT Pharmacometrics Syst Pharmacol; 2016 Apr 25; 5(4):222-32. PubMed ID: 27299709
    [Abstract] [Full Text] [Related]

  • 7. Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study.
    Medina A, Raskob G, Ageno W, Cohen AT, Brekelmans MPA, Chen CZ, Grosso MA, Mercuri MF, Segers A, Verhamme P, Vanassche T, Wells PS, Lin M, Winters SM, Weitz JI, Büller HR.
    Thromb Haemost; 2017 Dec 25; 117(12):2406-2414. PubMed ID: 29212128
    [Abstract] [Full Text] [Related]

  • 8. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial.
    Verhamme P, Wells PS, Segers A, Ageno W, Brekelmans MP, Cohen AT, Meyer G, Grosso MA, Raskob G, Weitz JI, Zhang G, Buller H.
    Thromb Haemost; 2016 Sep 27; 116(4):747-53. PubMed ID: 27440518
    [Abstract] [Full Text] [Related]

  • 9. Edoxaban: A direct oral anticoagulant.
    Poulakos M, Walker JN, Baig U, David T.
    Am J Health Syst Pharm; 2017 Feb 01; 74(3):117-129. PubMed ID: 28122753
    [Abstract] [Full Text] [Related]

  • 10. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.
    Raskob GE, van Es N, Segers A, Angchaisuksiri P, Oh D, Boda Z, Lyons RM, Meijer K, Gudz I, Weitz JI, Zhang G, Lanz H, Mercuri MF, Büller HR, Hokusai-VTE investigators.
    Lancet Haematol; 2016 Aug 01; 3(8):e379-87. PubMed ID: 27476789
    [Abstract] [Full Text] [Related]

  • 11. Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study.
    Di Nisio M, van Es N, Carrier M, Wang TF, Garcia D, Segers A, Weitz J, Buller H, Raskob G.
    J Thromb Haemost; 2019 Nov 01; 17(11):1866-1874. PubMed ID: 31271705
    [Abstract] [Full Text] [Related]

  • 12. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists.
    Brekelmans MP, Bleker SM, Bauersachs R, Boda Z, Büller HR, Choi Y, Gallus A, Grosso MA, Middeldorp S, Oh D, Raskob G, Schwocho L, Cohen AT.
    Thromb Haemost; 2016 Jul 04; 116(1):155-61. PubMed ID: 27010092
    [Abstract] [Full Text] [Related]

  • 13. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
    Raskob G, Cohen AT, Eriksson BI, Puskas D, Shi M, Bocanegra T, Weitz JI.
    Thromb Haemost; 2010 Sep 04; 104(3):642-9. PubMed ID: 20589317
    [Abstract] [Full Text] [Related]

  • 14. Direct factor Xa inhibitor edoxaban: from bench to clinical practice.
    Brekelmans M, Middeldorp S, Coppens M.
    Expert Rev Hematol; 2015 Dec 04; 8(6):707-25. PubMed ID: 26560872
    [Abstract] [Full Text] [Related]

  • 15. Edoxaban: a new oral direct factor xa inhibitor.
    Camm AJ, Bounameaux H.
    Drugs; 2011 Aug 20; 71(12):1503-26. PubMed ID: 21861537
    [Abstract] [Full Text] [Related]

  • 16. Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape?
    Gibson CM, Finks SW.
    Am J Med; 2017 Aug 20; 130(8):900-906. PubMed ID: 28390791
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study.
    Preblick R, Kwong WJ, White RH, Goldhaber SZ.
    Hosp Pract (1995); 2015 Aug 20; 43(5):249-57. PubMed ID: 26549305
    [Abstract] [Full Text] [Related]

  • 18. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study.
    Raskob G, Ageno W, Cohen AT, Brekelmans MP, Grosso MA, Segers A, Meyer G, Verhamme P, Wells PS, Lin M, Winters SM, Weitz JI, Büller HR.
    Lancet Haematol; 2016 May 20; 3(5):e228-36. PubMed ID: 27132697
    [Abstract] [Full Text] [Related]

  • 19. Edoxaban, a Novel Oral Factor Xa Inhibitor.
    Minor C, Tellor KB, Armbruster AL.
    Ann Pharmacother; 2015 Jul 20; 49(7):843-50. PubMed ID: 25855704
    [Abstract] [Full Text] [Related]

  • 20. Edoxaban: Review of pharmacology and key phase I to III clinical trials.
    Plitt A, Giugliano RP.
    J Cardiovasc Pharmacol Ther; 2014 Sep 20; 19(5):409-16. PubMed ID: 24607764
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.